Disdained by the market! Goldman Sachs: Today's pharmaceutical stocks are like "Coal Industrial Concept during the ESG peak period".
Goldman Sachs traders believe that the current trading performance of pharmaceutical stocks resembles "Energy stocks at the peak of the ESG era - as if they are about to perish," with the Sector's valuation relative to the S&P 500 Index having fallen to a historic low, creating the largest discount on record.
Express News | Terumo Says It and WuXi Biologics Enter Into Agreement on a Drug Product Plant in Leverkusen, Germany
China Securities Co.,Ltd. is bullish on pharmaceutical companies participating in industry consolidation domestically and actively exploring overseas markets.
Looking ahead to future investment opportunities in the Industry, the bank is Bullish on pharmaceutical companies stabilizing their domestic foundations, actively participating in industry consolidation, managing the rhythm and path externally, and proactively exploring overseas markets.
The Concept of Innovative Drugs has been severely attacked! Trump suddenly posts: We need to reduce drug prices in the USA by up to 80% immediately!
① The President of the USA, Trump, will sign an executive order on Monday aimed at reducing the prices of USA prescription pharmaceuticals and medications by 30% to 80% immediately; ② The executive order will implement a "most-favored-nation policy," aligning the prices paid in the USA with those of the country with the lowest drug prices in the world; ③ Trump referred to this executive order as "one of the most important executive orders in USA history," expecting it to save trillions of dollars.
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
【Brokerage Focus】CITIC SEC: The performance disparity in the Medical industry is accelerating, and policy trends are clear.
Jinwu Financial News | CITIC SEC stated that in 2024, the overall revenue of medical listed companies under the CITIC SEC industry classification will decrease by 0.62% year-on-year, with a net income attributable to the parent company declining by 8.48%. Both revenue and profit experience negative growth, while indicators such as gross margin, net margin, and Cash / Money Market / revenue have seen a decline compared to 2022 and 2023. In Q1 2025, the overall revenue of medical listed companies will decrease by 4.56% year-on-year, with a net income attributable to the parent company declining by 11.28%, putting pressure on performance. Although negative growth is still observed in the overall healthcare industry's performance for 2024 and Q1 2025, various subsidiary sectors are...
The Innovative Drugs Concept continues to adjust, BEIGENE (06160) drops 7.31%. Institutions indicate that the most worthy area of focus in the pharmaceutical Sector remains the Innovative Drugs track.
Jingwu Financial News | The Innovative Drugs Concept continues to adjust, with CanSino (01167) down 13.95%, BEIGENE (06160) down 7.31%, JUNSHI BIO (01877) down 6.75%, REMEGEN (09995) down 6.6%, and WUXI BIO (02269) down 6.24%. Sinolink's Research Reports indicate that the most noteworthy area in the pharmaceutical Sector will still be the Innovative Drugs track, as they believe that grasping investment opportunities in innovative pharmaceuticals will be the main theme of pharmaceutical investment throughout 2025, focusing on leading innovative drugs going overseas and leading combination of generics and innovative drugs, while also actively paying attention to...
Trending Industry Today: BEIGENE Leads Losses In Biotechnology Stocks
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
WUXI BIO issued 5.22 million shares of common stock according to the stock option plan.
WUXI BIO (02269) announced that on May 2, 2025, the company will issue 5.22 million ordinary shares to exercise Options according to the pre-IPO share option plan adopted on January 5, 2016 (revised on August 10, 2016).
Hong Kong Stock Morning Report | The U.S. actively conveyed information to China hoping to engage in talks, and May Day tourism sets another record.
① The USA proactively conveyed messages to China hoping to engage in talks, and China responded by stating it is currently evaluating. ② The USA's GDP decreased by an annualized rate of 0.3% in the first quarter, marking its first contraction since 2022. ③ The three major US stock indexes collectively fell on Monday, with mixed performances in Chinese stocks. ④ Buffett unexpectedly announced his resignation as CEO of Berkshire by the end of the year. ④ The "May Day" travel season has set a new record for the "most popular" in history.
WUXI BIO: Annual Report 2024
Guotou Securities: The investment and financing environment for Innovative Drugs is rebounding, CXO Orders and performance improvements are expected.
Global investment and financing in Innovative Drugs continues to improve, and a recovery in R&D demand is anticipated; new Orders are recovering in a timely manner, and there is optimism for improved CXO performance in 2025.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Wuxi Biologics' Growth Trajectory Stable But Tariff Risks Linger -- Market Talk
WUXI BIO (02269) issued 4.1654 million shares due to the exercise of Options.
WUXI BIO (02269) announced that from April 14 to April 23, 2025, due to the exercise of Options...
WUXI BIO has been rated as a leader in climate change by CDP for two consecutive years.
- Firmly implement commitments to combat climate change and actively respond to the United Nations Sustainable Development Goals. - Actively support the annual initiative of "Earth Day" — Action with you, Strength for the Earth, co-creating a sustainable development paradigm. Shanghai, April 22, 2025 /PR Newswire/ -- WUXI BIO, a global leading contract research, development, and manufacturing (CRDMO) service company, announced that it has received high recognition from the global environmental non-profit organization CDP for its outstanding performance and transparent disclosure in addressing climate change, achieving an A- rating for two consecutive years.
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
Trending Industry Today: INNOCARE Leads Gains In Biotechnology Stocks